BCYC

Bicycle is a pre-commercial oncology company whose entire investment case rests on a clinical pipeline we have no efficacy data on — nuzefatide pevedotin (EphA2 BDC) and, most importantly, zelenectide pevedotin (Nectin-4 BDC) now in the Duravelo-2 Phase II/III registrational trial in metastatic urothelial cancer. FY2025 revenue of $72.6M (+105.8%) is collaboration/milestone income, not durable product sales, so the -340% operating margin and -$219M net loss are the real signal: this is a research engine, not a business, with R&D up 38.9% to $240M and operating cash flow of -$250M and worsening.

The striking fact is the valuation. At $4.35 the market cap is $302M against $628M of cash and near-zero net debt (liabilities/equity just 0.18x) — the stock trades at roughly half of net cash (~$9.05/share) and well under book equity ($610M, ~$8.79/share). The market is effectively pricing the pipeline at less than nothing and betting the cash gets burned. With $628M against a ~$250M annual burn, runway is only ~2.5 years, and the burn is accelerating, so dilutive financing before any decisive readout is a real risk despite share count being flat so far.